{
    "clinical_study": {
        "@rank": "36824", 
        "arm_group": [
            {
                "arm_group_label": "EZ Shot 2 (Olympus America Inc., Center Valley, PA, USA) 22 g", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Expect\u2122 (Boston Scientific Natick, MA, USA) 22 gauge needle", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "EchoTip\u00ae Ultra (Cook Endoscopy, Winston-Salem, NC, USA) 22 g", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Obtaining a sample from a lesion in the gastrointestinal tract by endoscopic ultrasound (a\n      flexible tube with a camera and small ultrasound machine at its end )requires the use of a\n      needle for taking the sample from the lesion or what we call \"Fine needle aspiration (FNA)\".\n      Currently, FNA is done by three commercially available needles. These needles are used\n      routinely in our institution for FNA. The data regarding the safety and the successfulness\n      of any of these needles are lacking. We sought to compare all three commercially available\n      needles in a prospective manner."
        }, 
        "brief_title": "The Cellularity Yield of Three Different 22-gauge Endoscopic Ultrasound Fine Needle Aspiration Needles", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pancreatic or Peripancreatic Lesions", 
            "Lesions in the Esophagus, Stomach, Duodenum or Rectum", 
            "Mediastinal ( Chest) Masses", 
            "Enlarged Lymph Nodes"
        ], 
        "condition_browse": {
            "mesh_term": "Lymphatic Diseases"
        }, 
        "detailed_description": {
            "textblock": "The following are being done only for research purposes; prior to performing the FNA, The\n      patient will be randomized to one of the three commercially available FNA needles. At this\n      time, all needles are considered equivalent and there is no medical necessity to pick one\n      over another. The sample obtained by the needle will be assigned a quality score based on\n      certain parameters of the sample such as the abundance of diagnostic cells and the presence\n      of blood. We are going to collect certain information about your procedure such as the\n      complications of the procedure, number of needle passes and final diagnosis."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Adult patients (18-88) who are undergoing EUS FNA of pancreatic or peripancreatic\n             lesions\n\n          2. Adult patients (18-88) who are undergoing EUS FNA of submucosal masses in the\n             esophagus, stomach, duodenum or rectum\n\n          3. Adult patients (18-88) who are undergoing EUS FNA of mediastinal masses.\n\n          4. Adult patients (18-88) who are undergoing EUS FNA of enlarged lymph nodes\n\n        Exclusion Criteria:\n\n          1. Patients younger than 18 yrs old or older than 88 yrs.\n\n          2. Pregnant patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "88 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916421", 
            "org_study_id": "E12097"
        }, 
        "intervention": {
            "arm_group_label": [
                "EZ Shot 2 (Olympus America Inc., Center Valley, PA, USA) 22 g", 
                "Expect\u2122 (Boston Scientific Natick, MA, USA) 22 gauge needle", 
                "EchoTip\u00ae Ultra (Cook Endoscopy, Winston-Salem, NC, USA) 22 g"
            ], 
            "intervention_name": "Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pancreatic adenocarcinoma", 
            "lymphadenopathy", 
            "Endoscopic ultrasound"
        ], 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "contact": {
                "last_name": "Mohamed O Othman, MD", 
                "phone": "914-545-6618"
            }, 
            "facility": {
                "address": {
                    "city": "El Paso", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "79905"
                }, 
                "name": "Texas Tech University Health Sciences Center at El Paso"
            }, 
            "investigator": {
                "last_name": "Mohamed O Othman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cellularity score will be assessed by the cytopathologist using the scoring system from 0 to 10 score. This scoring system evaluate the amount of blood, malignant cells and contaminant cells. The system is a modified form Mair et al study. \" Mair S, Dunbar F, Becker PJ, Du Plessis W. Fine needle cytology--is aspiration suction necessary? A study of 100 masses in various sites. Acta cytologica 1989;33:809-13.\"", 
            "measure": "1. Compare the overall diagnostic accuracy of the three commercially available 22 gauge EUS needles", 
            "safety_issue": "No", 
            "time_frame": "2 days after the procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916421"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The patient will be contacted after the procedure by one week to review any procedure complications. The patient's medical records may be reviewed for up to 6 months after the procedure to review the surgical resection results or the long-term follow-up results. If the patient receives his further care in another hospital, the patient will be contacted by phone for follow-up for a maximum period of 6 months.", 
                "measure": "Compare the complication rate between the three commercially available 22 gauge EUS needles.", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 month after the procedure"
            }, 
            {
                "description": "The number of passes required to reach the diagnosis", 
                "measure": "Compare the number of FNA needles passes required to reach the diagnosis.", 
                "safety_issue": "No", 
                "time_frame": "During the procedure ( 30 -45 minutes)"
            }, 
            {
                "description": "The ability of the needle to perform the intended purpose of the procedure ( reach the lesion and obtain sufficient tissues)", 
                "measure": "Compare the technical success of the three commercially available 22 gauge EUS needles", 
                "safety_issue": "No", 
                "time_frame": "During the procedure ( 30-45 minutes)"
            }
        ], 
        "source": "Texas Tech University Health Sciences Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Texas Tech University Health Sciences Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}